Literature DB >> 30003813

Urocortin 3 Gene Transfer Increases Function of the Failing Murine Heart.

Dimosthenis Giamouridis1,2,3, Mei Hua Gao1,2, N Chin Lai1,2, Zhen Tan1,2, Young Chul Kim1,2, Tracy Guo1,2, Atsushi Miyanohara2, Matthijs W Blankesteijn3, Erik A L Biessen3,4, H Kirk Hammond1,2.   

Abstract

Peptide infusions of peptides the corticotropin releasing factor family, including urocortin 2, stresscopin, and urocortin 3 (UCn3), have favorable acute effects in clinical heart failure (HF), but their short half-lives make them unsuitable for chronic therapy. This study asked whether UCn3 gene transfer, which provides sustained elevation of plasma UCn3 levels, increases the function of the failing heart. HF was induced by transmural left ventricular (LV) cryoinjury in mice. LV function was assessed 3 weeks later by echocardiography. Those with ejection fractions (EF) <40% received intravenous saline or intravenous adeno-associated virus type-8 encoding murine UCn3 (AAV8.mUCn3; 1.9 × 1013 genome copies/kg). Five weeks after randomization, repeat echocardiography, assessment of LV function (+dP/dt, -dP/dt), and quantification of Ca2+ transients and sarcomere shortening in isolated cardiac myocytes were conducted, and assessment of LV Ca2+ handling and stress proteins was performed. Three weeks after myocardial infarction, prior to treatment, EFs were reduced (mean 31%, from 63% in sham-operated animals). Mice randomized to receive UCn3 gene transfer showed increased plasma UCn3 (from 0.1 ± 0.01 ng/mL in the saline group to 5.6 ± 1.1 ng/mL; n = 12 each group; p < 0.0001). Compared to mice that received saline, UCn3 gene transfer was associated with higher values for EF (p = 0.0006); LV +dP/dt (p < 0.0001), and LV -dP/dt (p < 0.0001). Cardiac myocytes from mice that received UCn3 gene transfer showed higher peak Ca2+ transients (p = 0.0005), lower time constant of cytosolic Ca2+ decline (tau, p < 0.0001), and higher rates of sarcomere shortening (+dL/dt, p = 0.03) and lengthening (-dL/dt, p = 0.04). LV samples from mice that received UCn3 gene transfer contained higher levels of SERCA2a (p = 0.0004 vs. HF) and increased amounts of phosphorylated troponin I (p = 0.04 vs. HF). UCn3 gene transfer is associated with improved Ca2+ handling and LV function in mice with HF and reduced EF.

Entities:  

Keywords:  AAV8; SERCA2a; gene therapy; heart failure with reduced EF

Mesh:

Substances:

Year:  2018        PMID: 30003813      PMCID: PMC6343192          DOI: 10.1089/hum.2018.103

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  26 in total

1.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors:  Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

2.  Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice.

Authors:  M H Gao; N C Lai; D M Roth; J Zhou; J Zhu; T Anzai; N Dalton; H K Hammond
Journal:  Circulation       Date:  1999-03-30       Impact factor: 29.690

3.  A novel model of cryoinjury-induced myocardial infarction in the mouse: a comparison with coronary artery ligation.

Authors:  Ewout J van den Bos; Barend M E Mees; Monique C de Waard; Rini de Crom; Dirk J Duncker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-04-29       Impact factor: 4.733

4.  Impact of beta-myosin heavy chain expression on cardiac function during stress.

Authors:  Maike Krenz; Jeffrey Robbins
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

5.  Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.

Authors:  Mihai Gheorghiade; Stephen J Greene; Piotr Ponikowski; Aldo P Maggioni; Jerzy Korewicki; Cezar Macarie; Marco Metra; Jacek Grzybowski; Serban-Ion Bubenek-Turconi; Waldemar Radziszewski; Allan Olson; Orlando F Bueno; Atalanta Ghosh; Lawrence I Deckelbaum; Lilian Y Li; Ayan R Patel; Andreas Koester; Marvin A Konstam
Journal:  Eur J Heart Fail       Date:  2013-03-06       Impact factor: 15.534

6.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Authors:  Sylvie Boutin; Virginie Monteilhet; Philippe Veron; Christian Leborgne; Olivier Benveniste; Marie Françoise Montus; Carole Masurier
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

7.  Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep.

Authors:  K Patel; M T Rademaker; C M J Kirkpatrick; C J Charles; S Fisher; T G Yandle; A M Richards
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

8.  Myofilament Calcium Sensitivity: Mechanistic Insight into TnI Ser-23/24 and Ser-150 Phosphorylation Integration.

Authors:  Hussam E Salhi; Nathan C Hassel; Jalal K Siddiqui; Elizabeth A Brundage; Mark T Ziolo; Paul M L Janssen; Jonathan P Davis; Brandon J Biesiadecki
Journal:  Front Physiol       Date:  2016-12-15       Impact factor: 4.566

9.  Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure.

Authors:  Colin G Stirrat; Sowmya Venkatasubramanian; Tania Pawade; Andrew J Mitchell; Anoop S Shah; Ninian N Lang; David E Newby
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

10.  Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice.

Authors:  N Chin Lai; Mei Hua Gao; Dimosthenis Giamouridis; Jorge Suarez; Atsushi Miyanohara; Jay Parikh; Stephen Hightower; Tracy Guo; Wolfgang Dillmann; Young-Chul Kim; Julieta Diaz-Juarez; H Kirk Hammond
Journal:  Hum Gene Ther       Date:  2015-04-09       Impact factor: 5.695

View more
  4 in total

Review 1.  Current Landscape of Heart Failure Gene Therapy.

Authors:  Jake M Kieserman; Valerie D Myers; Praveen Dubey; Joseph Y Cheung; Arthur M Feldman
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

Review 2.  Urocortin Role in Ischemia Cardioprotection and the Adverse Cardiac Remodeling.

Authors:  Eva M Calderón-Sánchez; Débora Falcón; Marta Martín-Bórnez; Antonio Ordoñez; Tarik Smani
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

Review 3.  Corticotropin-Releasing Factor Family: A Stress Hormone-Receptor System's Emerging Role in Mediating Sex-Specific Signaling.

Authors:  Lahari Vuppaladhadiam; Cameron Ehsan; Meghana Akkati; Aditi Bhargava
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

4.  Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives.

Authors:  Darnel Prakoso; Mitchel Tate; Miles J De Blasio; Rebecca H Ritchie
Journal:  Clin Sci (Lond)       Date:  2021-06-11       Impact factor: 6.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.